The role of the peripheral sympathetic nervous system in the natriuresis following central administration of an I1 imidazoline agonist, moxonidine

British Journal of Pharmacology
S B Penner, D D Smyth

Abstract

1. Central administration of the I1-imidazoline receptor agonist moxonidine increases sodium excretion without alteration of blood pressure. In the present study we determined whether this natriuretic action was mediated through a decrease in activity of the sympathetic nervous system, as has been reported for the antihypertensive action of this compound. Interruption of the sympathetic nervous system was achieved with prazosin (alpha 1-adrenoceptor antagonist) and renal denervation. 2. In pentobarbitone-anaesthetized Sprague-Dawley rats, intracerebroventricular (i.c.v.) injection of moxonidine alone increased urine volume and sodium excretion. Prazosin (0.15 mg kg-1, i.v.) alone decreased urine flow rate and sodium excretion as compared to the vehicle controls. In the presence of prazosin, i.c.v. injection of moxonidine failed to increase sodium excretion or urine volume as compared to animals which received the prazosin alone. 3. The administration of moxonide (i.c.v.) to sham renal-denervated animals caused an increase in urine flow rate, urine sodium excretion, osmolar clearance and free water clearance. The increase in sodium excretion and osmolar clearance were completely attenuated in renal denervated rats, however, urin...Continue Reading

References

Mar 26, 1991·European Journal of Pharmacology·R E GomezD J Reis
Apr 1, 1990·British Journal of Pharmacology·C M BrownA T Kilpatrick
Jan 1, 1985·Journal of Cardiovascular Pharmacology·R A GillisJ A Quest
Sep 1, 1989·Trends in Pharmacological Sciences·M C Michel, P A Insel
Mar 14, 1989·European Journal of Pharmacology·G BriccaP Bousquet
Dec 1, 1988·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·P ErnsbergerD J Reis
Sep 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·J N SinhaK P Bhargava
Feb 1, 1988·British Journal of Pharmacology·S B Penner, D D Smyth
Jul 12, 1995·Annals of the New York Academy of Sciences·S B Penner, D D Smyth
Aug 1, 1994·British Journal of Pharmacology·S B Penner, D D Smyth
Apr 1, 1993·British Journal of Pharmacology·D R AllanD D Smyth

❮ Previous
Next ❯

Citations

Dec 16, 1998·Journal of the Autonomic Nervous System·D D Smyth, S B Penner
Aug 19, 1999·Brain Research Bulletin·C Farsang, J Kapocsi
Jan 1, 1997·Clinical and Experimental Pharmacology & Physiology·R G EvansW P Anderson
Jul 23, 1999·Annals of the New York Academy of Sciences·D D Smyth, S B Penner
Jul 5, 2005·Expert Opinion on Investigational Drugs·P A van Zwieten
Mar 28, 2009·European Journal of Pharmacology·Carina A F de AndradeJosé V Menani
Sep 24, 2004·The Annals of Pharmacotherapy·Chuen-Der KaoKwong-Kum Liao
Jun 17, 2000·Hypertension·S Mukaddam-Daher, J Gutkowska
May 5, 2001·Expert Opinion on Pharmacotherapy·S A Doggrell
Feb 25, 2011·Journal of Hypertension·Sandra L BurkeGeoffrey A Head
Oct 23, 2013·Pharmacological Reports : PR·Magdalena WróblewskaApolonia Rybczyńska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.